Unconvincing Pfizer and uncertain crucifixions.

The article focuses on a response of Pfizer regarding a research paper published in the March 2006 issue of the "Journal of the Royal Society of Medicine" on the risk of myocardial infarction with celecoxib therapy. The findings of the journal are extremely misleading and has an incomplete review of data according to Mark Crotty, general manager of Pfizer New Zealand. It says that a systematic review and meta-analysis does not contain all the available research in the final analysis.